Pharmacokinetic properties, induction of interferon, and efficacy of selected 5-halo-6-phenyl pyrimidinones, bropirimine analogues, in a model of severe experimental autoimmune encephalomyelitis

International Journal of Immunopharmacology

Volumn 21, Issue 10, 1999, Pages 647-662

  Vroegop, S M ^a   Chapman, D L ^a   Decker, D E ^a   Galinet, L A ^a   Brideau, R J ^a   Ready, K A ^a   Dunn, C J ^a   Buxser, S E ^a  

^a PFIZER INC   (United States)

Author keywords

interferon; Bropirimine analogues; EAE; Experimental autoimmune encephalomyelitis; IFN ; Leukocyte infiltration; Multiple sclerosis

Indexed keywords

BROPIRIMINE; INTERFERON; PNU 54461; PNU 54462; PNU 56169; PNU 63693; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; CYTOSINE; DRUG DERIVATIVE; GAMMA INTERFERON; INTERFERON INDUCING AGENT;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; INTERFERON PRODUCTION; INTRAGASTRIC DRUG ADMINISTRATION; LEUKOCYTE MIGRATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; ANIMAL; BLOOD; DOSE RESPONSE; IMMUNOLOGY; LEUKOCYTE; PATHOLOGY; SPINAL CORD;

ANIMALS; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; INTERFERON INDUCERS; INTERFERON TYPE II; LEUKOCYTES; MICE; SPINAL CORD;

EID: 0032846847     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(99)00040-5     Document Type: Article

References (27)

1. Baron J.L., Madri J.A., Ruddle N.H., Hashim G., Janeway C.A. Surface expression of alpha-4 integrin by CD4 T cells is required for the entry into brain parenchyma. J. Exp. Med. 177:1993;57-68.
2. Bauer J., Sminia T., Wouterlood F.G., Dijkstra C.D. Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis. Journal of Neuroscience Research. 38:1994;365-375.
3. Bauer J., Huitinga I., Zhao W., Lassmann H., Hickey W.F., Dijkstra C.D. The role of macrophages, perivascular cells, and microglia cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia. 15:1995;437-446.
4. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D., Veromaa T., Waisman A., Gaur A., Conlon P., Ling N., Fairchild P.J., Wraith C.D., O'Garra A., Fathman C.G., Steinman L. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:1996;343-346.
5. Chapman D.L., Vroegop S.M., Galinet L.A., Ready K.A., Dunn C.J., Vidmar T.J., Buxser S.E. Quantitative evaluation of leukocyte infiltration into the spinal cord in a model of experimental autoimmune encephalomyelitis: Statistical-analytical techniques for use in evaluating drugs. Int. J. Immunopathol. 11:1998;117-137.
6. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science. 265:1994;1237-1240.
7. Duong T.T., St Louis J., Gilbert J.J., Finkelman F.D., Strejan G.H. Effect of anti-interferon-γ and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse. J. Neuroimmunol. 36:1992;105-115.
8. Hamilton R.D., Wynalda M.A., Fitzpatrick F.A., Teagarden D.L., Hamdy A.H., Snider B.G., Weed S.D., Stringfellow D.A. Comparison between circulating interferon and drug levels following administration of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP) to different animal species. J. Interferon Res. 2:1982;317-327.
9. Huitinga I., Vanrooijen N., deGroot C.J.A., Uitdehaag B.M.J., Dijkstra C.D. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172:1990;1025-1033.
10. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
11. Jameson B.A., McDonnell J.M., Marini J.C., Korngold R. A rationally designed analogue inhibits experimental allergic encephalomyelitis. Nature. 368:1994;744-746.
12. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., Ben-Nun A., Kalland T., Abramsky O. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann. Neurol. 34:1993;654-660.
13. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R., Ovadia H., Kalland T., Abramsky O. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. USA. 90:1993;6400-6404.
14. Kent S.J., Karlick S.J., Cannon C., Hines D.K., Yednock T.A., Fritz L.C., Horner H.C. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58:1995;1[puen10.
15. Korner H., Goodsall A.L., Lemckert F.A., Scallon B.J., Ghrayeb J., Andrew A.L., Sedgwick J.D. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA. 92:1995;11066-11070.
16. Lotzova E., Savary C.A., Stringfellow D.A. 5-halo-6-phenyl pyrimidinones: New molecules with cancer therapeutic potential and interferon-inducing capacity are strong inducers of murine natural killer cells. J. Immunol. 130:1983;965-969.
17. Raine C.S. Analysis of autoimmune demyelination: Its impact upon multiple sclerosis. Lab. Invest. 50:1984;608-635.
18. Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., Padula S.J., Clark R.B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1990;1193-1200.
19. Rudick R.A., Selby W., Durelli L. Treatment of multiple sclerosis with type I interferons. In: Multiple Sclerosis, Advances. Goodkin D.E., Rudick R.A. Clinical Trial Design, Treatment and Future Perspectives. 1996;Springer, London, Berlin, Heidelberg, New York, Barcelona, Budapest, Hong Kong, Milan, Paris, Santa Clara, Singapore, and Tokyo.
20. Skulnick H.I., Weed S.D., Eidson E.E., Renis H.E., Wierenga W., Stringfellow D.A. Pyrimidinones. I. 2-amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-inducing antiviral agents. J. Med. Chem. 28:1985;1864-1869.
21. Stringfellow DA, Vandenberg HC, Weed SD, Interferon induction by 5-halo-6-phenyl pyrimidinones, Curr. Chemother. Inf. Dis. 1980;1406-1408.
22. Swanborg R.H. Experimental autoimmune encephalomyelitis in rodents as a model for demyelinating disease. Clin. Immunol. Immunopath. 77:1996;4-13.
23. The Guide for the Care and Use of Animals. 1996;National Research Council, National Academy Press, Washington, DC.
24. Traugott U., Raine C.S., McFarlin D.E. Acute experimental allergic encephalomyelitis in the mouse: Immunopathology of the developing lesion. Cell. Immunol. 91:1985;240-254.
25. Traugott U., McFarlin D.E., Raine C.S. Immunopathology of the lesion in chronic relapsing experimental autoimmune encephalomyelitis in the mouse. Cell. Immunol. 99:1986;395-410.
26. Vroegop S.M., Chapman D.L., Galinet L.A., Ready K.A., Brideau R.J., Dunn C.J., Buxser S.E. Pharmocology of the biological response modifier bropirimine (PNU-54461) on experimental autoimmune encephalomyelitis (EAE) in mice. Intl. J. Immunopharm. 21:1999;391-409.
27. Yu M., Nishiyama A., Trapp B.D., Tuohy V.K. Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Neuroimmunol. 64:1996;91-100.